Benzimidazole Dimer STING Modulators for Interferon Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases and conditions mediated by the STING pathway lack effective small molecule modulators that can selectively activate or inhibit type I interferon production, leading to inadequate therapeutic strategies for autoimmune, allergic, and infectious diseases, as well as cancer.
Innovation Solution
Development of benzimidazole dimers that modulate the activity of STING, acting as either agonists or antagonists to regulate type I interferon production, providing therapeutic benefits in conditions where STING modulation is beneficial.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule compounds are developed to modulate STING activity, then therapeutic efficacy for autoimmune, allergic, and infectious diseases is improved, but the complexity of drug discovery and development increases
Solution Approach 1:
The patent segments the STING modulation problem into two distinct therapeutic approaches: agonists (compounds of formula I) for enhancing immune response in infectious diseases and cancer, and antagonists (compounds of formula II) for suppressing immune response in autoimmune and allergic diseases. This segmentation allows targeted development of specific compound classes for different disease indications, improving therapeutic efficacy while managing discovery complexity through focused molecular design strategies.
2Reliability
If STING agonists are used to enhance immune response, then treatment of infectious diseases and cancer is improved, but risk of excessive immune activation and autoimmune reactions increases
Solution Approach 1:
The patent employs dynamic control of STING activation through reversible binding of agonist compounds to the STING protein. The compounds can be administered at controlled doses and durations, allowing the immune response to be enhanced when needed (for infectious diseases and cancer) while avoiding excessive or prolonged activation that could lead to autoimmune reactions. The reversible nature of the interaction provides temporal and dosage control over the immune modulation effect.
3Reliability
If STING antagonists are used to suppress immune response, then treatment of autoimmune and allergic diseases is improved, but susceptibility to infections and reduced cancer immunity increases
Solution Approach 1:
The patent applies partial action by using antagonist compounds (formula II) at doses and durations specifically tailored to suppress only the pathogenic immune responses in autoimmune and allergic diseases, while preserving sufficient baseline immune function to maintain protection against infections and cancer surveillance. This selective partial suppression avoids the harmful effects of complete or excessive immune shutdown.
4Measurement precision
If selective STING modulators are developed for specific disease indications, then therapeutic precision is improved, but the time and resources required for targeted drug development increase
Solution Approach 1:
The patent establishes a universal STING modulation platform where the same target (STING protein) and binding chemistry can be applied across multiple disease indications by simply switching between agonist and antagonist compound classes. The core molecular frameworks (formulas I and II) serve as universal templates that can be optimized for different indications through substituent variation, reducing overall development time and resources compared to developing entirely separate therapeutic mechanisms for each disease type.
Data Source
AI summary
This disclosure relates to compounds of formula (I), which are modulators of STING. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods of using compounds of formula (I) in the treatment or prevention of diseases ameliorated by the modulation of STING.